Crossroads Transforms Opioid Use Disorder Treatment
10 Sep 2024 //
BUSINESSWIRE
Kallyope Enters Phase 2 With First-in-class Oral Approach
27 Sep 2023 //
BUSINESSWIRE
Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors
06 Jun 2023 //
BUSINESSWIRE
Kallyope, Pioneers in Drug Discovery via Gut-Brain Axis, With New Appointments
06 Jul 2022 //
BUSINESSWIRE
Sosei Heptares and Kallyope Enter Collaboration for Novel GI GPCR Targets
17 May 2022 //
GLOBENEWSWIRE
Kallyope delays IPO to snag $236M series D for 22 programs
16 Feb 2022 //
BIOWORLD